Connect with us

International Circuit

Boston Scientific Announces Scheduled Presentations at TCT 2018

Boston Scientific Corporation announced key data that will be presented at the 30th Transcatheter Cardiovascular Therapeutics (TCT), the annual scientific symposium of the Cardiovascular Research Foundation, in San Diego, on September 21 – September 25. Data from the head-to-head IMPERIAL trial evaluating the ELUVIA Drug-Eluting Vascular Stent System and the Zilver PTX Stent for treatment of superficial femoral or proximal popliteal lesions will be featured during a late-breaking clinical trial session on Saturday, September 22. Two-year outcomes data from the REPRISE III study, a head-to-head comparison of the LOTUS Aortic Valve System to the CoreValve Evolut R in high-risk patients with severe aortic stenosis, will also be highlighted at the meeting.

“The data being presented at TCT will provide important clinical evidence to assist physicians to make informed treatment decisions for the patients they serve,” said Professor Ian Meredith, M.D., executive vice president and global chief medical officer, Boston Scientific. “We look forward to sharing the findings from the IMPERIAL trial, a first-of-its-kind large randomized safety and effectiveness trial, studying the use of drug-eluting stents for peripheral artery disease. Our investment in these key studies exemplifies our continued commitment to advancing science in the field of interventional vascular therapies, and ultimately, improving care for all patients.”

All presentations are listed in Pacific Time and will take place at the San Diego Convention Center.

Presentations of interest (listed chronologically)

Friday, September 21 – LOTUS Aortic Valve System: Final 5-Year Outcomes Of The REPRISE II Study: Long-Term Outcomes With the Fully Repositionable and Retrievable Lotus Transcatheter Aortic Valve: Nicolas Dumontiel, M.D., will present at 1:15 p.m. in Room 28D-E, Upper Level. LOTUS Aortic Valve System: Two-Year Outcomes After Transcatheter Aortic Valve Replacement With Mechanically- versus Self-Expandable Valves: Results From The REPRISE III Randomized Trial: Michael J. Reardon, M.D., will present at 1:30 p.m. in Room 28D-E, Upper Level.

Saturday, September 22 – ELUVIA Drug-Eluting Vascular Stent System: IMPERIAL: A Randomized Trial of Drug-Eluting Stents for Treatment of Femoropopliteal Artery Lesions: William A. Gray, M.D., will present at 10:21 a.m. in the Main Arena, Hall F, Ground Level.

Sunday, September 23 – PROMUS Element Plus Everolimus-Eluting Stent System: Final 5-Year Results in Unselected Patients Implanted With A Thin-Strut, Platinum-Chromium, Everolimus-Eluting Stent: the PROMUS Element Plus Us Post-Approval Study: David E. Kandzari, M.D., will present at 11:30 a.m. in the Exhibit Hall, Ground Level, at Moderated Posters 8. LOTUS Aortic Valve System: Paravalvular Leak in the RESPOND Post-Market Study- Predictors and Impact on 2-Year Clinical Outcomes Following TAVR With A Fully Repositionable and Retrievable Aortic Valve in Routine Clinical Practice: Jochen Wöhrle, M.D., will present at 2:57 p.m. in the Exhibit Hall, Ground Level, at Moderated Posters 5.

Monday, September 24 – SYNERGY Bioabsorbable Polymer Stent: Baseline Characteristics and 3-Month Outcomes of the EVOLVE Short DAPT Trial – A Prospective investigation of Abbreviated Antiplatelet Therapy in High Bleeding Risk Patients Treated With A Thin-Strut Bioabsorbable Polymer-Coated, Everolimus-Eluting Stent: Ajay J. Kirtane, M.D., will present at 10:30 a.m. in the Exhibit Hall, Ground Level, at Moderated Posters 6.

For more information, visit http://www.bostonscientific.com/en-US/medical-specialties/interventional-cardiology/conferences-and-events/tct.html or during TCT visit the Boston Scientific booth #507. The company will also host an investor event and webcast on Monday, September 24 from 9:00 – 10:00 a.m. PT to provide a business update and answer questions from investors about the Boston Scientific cardiovascular portfolio. The event will be accessible at www.bostonscientific.com/investors. A replay of the webcast will be accessible at www.bostonscientific.com/investors beginning approximately one hour following the completion of the event. In the US, the ELUVIA Stent System is an investigational device and is not available for sale. The LOTUS Valve system is not available for use or sale. – Medical Buyer Bureau

Copyright © 2024 Medical Buyer

error: Content is protected !!